On January 27, the US Food and Drug Administration (FDA) approved fam-trastuzumab deruxtecan-nxki for unresectable or metastatic hormone receptor-positive, HER2-low or HER2-ultralow breast cancer, as determined by an FDA-approved test, that has progressed on one or more endocrine therapies in the metastatic setting.

For more information, read the FDA announcement and the Daiichi Sankyo press release.

Posted on 2/20/25